TIMELINE

In 2015, Single Use Support GmbH founders, Johannes Kirchmair and Thomas Wurm, decided to combine their experiences gained in international technology sales and their specific knowledge concerning single use technology in the biopharma supplier industry with the aim to find solutions for certain pain points that Johannes had encountered during his 15 years in the single use segment of the biopharma industry

„It was no longer tolerable for me that some of the biggest pharmaceutical players on the globe could not solve obvious problems by their own efforts,” says Johannes Kirchmair. „This developed into an ever-growing challenge to find solutions ourselves.“

2020

Q3

THE SKY IS THE LIMIT

Single Use Support is growing more than ever, both in turnover and employees: to date, we are counting 55 employees and aim at an annual turnover of 40 million EUR. Compared to 2019, this is a growth rate of approx. 1300%.

We accompany several vaccine manufacturers that prepare for production of potential vaccines against COVID-19. Even though the vaccines are not approved by FDA/EMA yet, the production has already started. Since end of September, one of the frontrunning COVID-19 vaccines has been frozen by Single Use Support’s large scale freeze/thaw platform.

Hardware Solutions
The thriving business is accompanied with several hardware deliveries, naming RoSS.FILL, RoSS.pFTU Large scale and Lab scale, within shortest lead time. Additionally to our serial production, we also delivered our first optional solutions for bottles: RoSS.FILL with bottle filling rack and RoSS.pFTU Lab scale FLEX for filling and freezing bottles/rigid containers based on our standard technologies. Our technologies have been shipped in Q3 globally: USA, Canada, India, Spain, UK, Switzerland and Germany.

Consumable Solutions
More than 30,000 RoSS shells and more than 15,000 RoSS.KSET has been produced in 2020 – still counting. Our consumables are very well received by our trusted partners. Single Use Support will work on self-made manifolds to be able to provide the full equipment for filling and draining drug substance into single use bags from one hand.

Our whole portfolio can now be chosen in very short paths with the help of our brandnew configurator.

Q2

ON THE RISE

Thomas Wurm

„In Q2, we have broken new paths in many ways!"

Thomas Wurm / Owner & Founder

  • Accompanying the research & development of a COVID-19 vaccine: The technologies of Single Use Support have been applied for the management of potential vaccines against Covid-19. Our freeze and thaw platforms in different scales have been ordered and are already in use for clinical studies.
  • Entering India: One of the biggest companies in the emerging Indian biopharma market has ordered the whole BULK.STREAM for their therapies.
  • Kicking off serial production: Our scalable plate-based freeze and thaw platforms have shown great demand. We have gone into serial production and conducted FATs and SATs non-stop. Not even travel restrictions due to Covid-19 has stopped us to commission the platforms around the world – we have performed SAT partly virtually.
  • Introducing the SEED.STREAM: As additional field of application, single-use technologies help to take a shortcut in Biopharma upstream manufacturing process and boosts the next generation of seed train intensification. Discover the new SEED.STREAM.
  • Adjusting revenue target: the delightful sales development has led to an increase of 2020 revenue target. Johannes Kirchmair and Thomas Wurm have adjusted upwards to 15 million EUR.
  • Growing the team: in June 2020 we have reached the mark of 35 employees. However, we want to grow further.

Q1

WE GROW REGARDLESS OF POTENTIAL PITFALLS

At the beginning of 2020, the team in Kufstein will be expanded with many new employees. The team now includes 30 employees, who continue to raise their ambitious goals and process our customers' current orders. This expansion of staff inevitably led to an expansion of our production hall and office space in February 2020.

The rampant virus COVID-19, including the curfews imposed in March and April, does not prevent Single Use Support from producing and completing large-scale freezers and RoSS.FILL filling platforms. After all, in the development of vaccines against COVID-19, the biopharma industry trusts the technologies RoSS and RoSS.KSET in clinical studies. In addition, freezing and filling platforms were already delivered to customers in Q1.

Thus, more than ever, we can continue to pursue our vision with full force in these times, using our technologies to increase quality standards and thus patient safety and quality of life.

2019

Q4

_

In Q4 2019, Singe Use Support has established two entire liquid STREAM processes that we are able to supply to customers. Technologically leading. Safe for patients.

Due to a growing number of co-operations with partners from the biopharma industry as well as organizations like the FDA we are expecting a multi-dimensional need for our technologies. This will further drive our growth!

For further growth in the Asian region, we were able to get ambassadors from India and China on board - followed a little later by an ambassador from Japan - who now support us as a partner in business development in Asia.

Conclusion 2019:
We have come a step closer to a “considerably improved international standard for the biopharma liquid logistics process”.

Q3

_

In Q3 2019 we push our manufacturing output for BULK.STREAM to the next level, while at the same time massively driving our growth with the CGT.STREAM. More space again: We will expand significantly in terms of production facilities and office space.

Q2

_

In Q2 2019 we introduce another liquid STREAM, which is being developed.

Our biggest leap since we started:
Innovation requires fresh ideas and the right people with a will to implement those ideas. Organic growth on a high level requires a market like the biopharma market, which is growing at a steady rate and has a requirement for improved standards. It is a development that we believe in and so we are planning to take the biggest leap yet with our young company in 2019!

Read more

Q1

_

Q1 2019 witnesses the launch of the CGT.STREAM and the first shipment to partners from the biopharma industry.

2018

Q4

_

Q4 2018 saw us being awarded with the Tyrolean Innovation Prize. We were also voted second best young entrepreneurs in western Austria, and at the same time we received the biggest order to date from the US. Johannes was invited to introduce the MITS.2D to a panel of 60 international experts at the FDA headquarters in Washington, D.C. – what an accolade!

Thomas Wurm

„While we are growing with our BULK.STREAM and getting our first products for a secure CAR-T logistics process ready for the market, yet another new opportunity is presenting itself. We have received an invitation to establish a new business sector together with a biopharmaceutical player...“

Johannes Kirchmair / Owner & Founder

Conclusion 2018:
Like a movie.

What started with a vision in a garage in 2016 and was developed and made ready for the market in 2017, was gaining ever more traction in 2018. Furthermore, we have been witnessing growing demand regarding CAR-T logistics solutions since mid-2018. The term ‘patient safety’ is given a new meaning.

Single Use Support GmbH nowadays is a:

  • 2,5-year-old organization
  • fast-growing company (organically)
  • technology leader already
  • well-recognized company on the biotech world

Q3

_

In Q3 2018, Single Use Support GmbH grew to ten employees.
Furthermore we received the biggest order to date from yet another biopharmaceutical player.

Q1

_

The Q1 2018 started with an extensive funding program, which allowed us to invest in further research and development.
At the same time we received a major order from another player in the biopharma industry – this time for our RoSS shell system.

2017

Q4

Next Step – We need more Space!

Q4 2017 saw us move into our new 800 m2 residence with our first four employees. It comprised an office, an R&D area and sufficient production floor space. We managed to book the first serious major order from a pharmaceutical company and got to work in our new premises.

Thomas Wurm

„We conceived and developed the BULK.STREAM. This process gives biopharmaceutical companies access to a new and almost 100% secure liquid logistics process on the basis of an industry standard, the single use bag.“

Thomas Wurm / Owner & Founder

Conclusion 2017:
Year two. What a year.

From the garage to serious company-building.
What started as a vision was – only one year later – perceived as a technological leader in the biopharma industry.

Wow!

Q3

Fifth instance – the biopharma industry.

Problem to solve:
SUSupport = Super-small startup. Biopharma = Giants. Is there a chance to get together?

Q3 2017 saw a first serious turnover generated with our testing system MITS.2D.
At the same time it became obvious that the first pharmaceutical industry partners recognized the advantages of RoSS. And we can fully agree with the following: It costs a tremendous amount of energy to replace an established process or technology, even if the new technology is superior.

If I had asked people what they wanted, they would have said faster horses. Henry Ford.

Problem Solved.

Thomas Wurm

„A dream is coming true for the medical industry. While we are still busy convincing pharmaceutical giants of our BULK.STREAM and its unbelievable advantages, the EU follows the US in approving the first CAR-T cell therapies. With BULK.STREAM we have not even processed the tip of the iceberg in terms of possible options, and are yet being commissioned to scale down our technology in order to supply the medical industry with a secure logistical basis for this imminent mega-trend.“

Thomas Wurm / Owner & Founder

Q2

Second instance – single use bag handling & transport.

Problem to solve:
Protection, handling, storage, freeze & thaw suitability, transport

In Q2 2017 RoSS was ready to launch. RoSS is a superior shell system for single use bags of all standard sizes and manufacturers. RoSS is the acronym for Robust Storage and Shipping System. Usability, materials and its modular design found immediate positive response in the industry. However, RoSS is not only a shell; it offers rack compatibility, which was the basis for our vision of the entire process. RoSS shell systems can be stored at a larger number in the RoSS.Ship stainless steel rack container with its active and passive freezing options and GPS tracking functionality.

Solved & New Standard established!

Thomas Wurm

„We founded Single Use Support GmbH because we realized that there is a technological gap in biotech industry. We did not expect that we will grow that fast, but now we see that the industry is hungry for our solutions. Our goal is to form a trusted global player. Customers and regulators confirm that we are on the right way.”

Thomas Wurm / Owner & Founder

Third instance – filling and draining of the single use bag.

Problem to solve:
Duration & sterility, single use and reuse technology touch points

Also in Q2 2017, we introduced a new standard for the simultaneous filling of 20 RoSS units and more with the RoSS.FILL. Apart from ease of handling and the time-saving factor it constitutes a homogenous closed process that equally systemizes filling and draining. In order to keep the process quality at a consistently high level, RoSS.FILL provides statistical data and evidence for each process.

Solved & New Standard established!

Fourth instance – substance freeze & thaw.

Problem to solve:
Duration

Q2 2017 also saw the launch of our freeze-thaw platform, which by now is available in different sizes and performance categories. Our system enables systemic freezing and thawing. In order to keep the process quality at a consistently high level, the Freeze & Thaw Platform provides statistical data and evidence for each process.

Solved & New Standard established!

Thomas Wurm

“Clients told us that they have issues in this process step. (testing, filling, freezing, storage, shipping, thawing and emptying of single use bags with drug substance) We came up with technical solutions. We played ping-pong with some customers to fine tune the ideas, and finally they bought into it.”

Johannes Kirchmair / Owner & Founder

Q1

First instance – the single use bag.

Problem to solve:
Integrity – material deficiencies / bio contamination / loss of drug substance

In Q1 2017 we started with the development of MITS, a mobile testing system for single use bags of all standard sizes (up to 50 L) and manufacturers, working on the basis of helium. MITS.2D is mobile, fast and much more precise in its measurement than anything available on the market thus far.

Solved.

2015 - 2016

The decision to launch Single Use Support was made and our vision elaborated. We transformed a garage into an office where we researched, developed and manufactured our first prototypes.